<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136174</url>
  </required_header>
  <id_info>
    <org_study_id>1199.31</org_study_id>
    <nct_id>NCT01136174</nct_id>
  </id_info>
  <brief_title>Safety and PK Study of BIBF 1120 in Japanese Patients With IPF</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled (Within a Dose Group) Study to Evaluate Safety and Pharmacokinetics of Multiple Rising Doses of BIBF 1120 at 50 mg Bid (14 Days), 100 mg Bid (14 Days), and 150 mg Bid (28 Days) p.o., on Top of Standard Medical Care With Stratification According to Pirfenidone Use, in Japanese Patients With Idiopathic Pulmonary Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate safety of BIBF 1120 in Japanese patients with idiopathic pulmonary fibrosis
      (IPF), with and without pirfenidone background treatment.

      To assess pharmacokinetics of BIBF 1120 in Japanese patients, with and without pirfenidone
      background treatment.

      To assess pharmacokinetics of pirfenidone in Japanese patients, alone and in combination with
      BIBF 1120 treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug-related Adverse Events</measure>
    <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
    <description>The number of patients with drug-related adverse events stratified according to pirfenidone use in each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone</measure>
    <time_frame>pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)</time_frame>
    <description>AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone in the time frame mentioned.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone</measure>
    <time_frame>pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone</measure>
    <time_frame>pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)</time_frame>
    <description>AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone in the time frame mentioned.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone</measure>
    <time_frame>pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)</measure>
    <time_frame>Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose</time_frame>
    <description>AUC0-4,ss was calculated as the area under the curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) in the time frame mentioned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)</measure>
    <time_frame>Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)</measure>
    <time_frame>Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose</time_frame>
    <description>AUC0-4,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) in the time frame mentioned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)</measure>
    <time_frame>Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)</measure>
    <time_frame>Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose</time_frame>
    <description>AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after lunch) in the time frame mentioned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)</measure>
    <time_frame>Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg Without BIBF 1120 (after lunch)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)</measure>
    <time_frame>Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose</time_frame>
    <description>AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) in the time frame mentioned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)</measure>
    <time_frame>Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal Due to Adverse Event</measure>
    <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
    <description>Number of patients prematurely discontinued from trial medication due to adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background</measure>
    <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
    <description>Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - No pirfenidone background</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background</measure>
    <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
    <description>Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - With pirfenidone background</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>baseline and day 35</time_frame>
    <description>Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>baseline and day 35</time_frame>
    <description>Change from baseline in pulse rate at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)</measure>
    <time_frame>baseline and day 35</time_frame>
    <description>Change in diffusing capacity for carbon monoxide (DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)</measure>
    <time_frame>baseline and day 35</time_frame>
    <description>Change in Diffusing Capacity for Carbon Monoxide percent of predicted (%DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>baseline and day 35</time_frame>
    <description>Change in forced expiratory volume in 1 second (FEV1) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function Measurement: Forced Vital Capacity (FVC)</measure>
    <time_frame>baseline and day 35</time_frame>
    <description>Change in forced vital capacity (FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)</measure>
    <time_frame>baseline and day 35</time_frame>
    <description>Change in Forced Vital Capacity percent of predicted (%FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>BIBF 1120 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose for cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBF 1120 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle dose for cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBF 1120 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose for cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for cohort 1,2,3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID for cohort 1,2,3</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <description>50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively</description>
    <arm_group_label>BIBF 1120 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <description>50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively</description>
    <arm_group_label>BIBF 1120 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <description>50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively</description>
    <arm_group_label>BIBF 1120 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of idiopathic pulmonary fibrosis (IPF) according to American Thoracic
             Society (ATS) /European Respiratory Society (ERS) guideline

          2. Forced vital capacity (FVC) 50-90%

          3. Diffusing capacity for carbon monoxide (DLCO) 30-79%

          4. For patients on pirfenidone, have been on a steady dose for at least 3 months

        Exclusion criteria:

          1. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) &gt; 1.5 x upper limit
             of normal range (ULN) at screening.

          2. Bilirubin &gt; 1.5 x ULN at screening.

          3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC &lt;0.7) at screening.

          4. Continuous oxygen supplementation.

          5. Active infection at screening or randomisation.

          6. Being treated with any of the following concomitant medications.

               -  Oral corticosteroid medication at unstable dose

               -  ketoconazole or atazanavir

          7. Patients who are expected to go on to lung transplantation, have rapidly deteriorating
             disease, or have a life expectancy less than 3 months from screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1199.31.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.31.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamamatsu, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.31.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.31.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.31.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakai, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.31.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seto, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.31.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimotsuke,Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.31.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <results_first_submitted>November 14, 2014</results_first_submitted>
  <results_first_submitted_qc>December 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2015</results_first_posted>
  <disposition_first_submitted>May 16, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 16, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 29, 2014</disposition_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo oral administration twice a day</description>
        </group>
        <group group_id="P2">
          <title>BIBF 1120 50 mg</title>
          <description>BIBF 1120 50 mg oral administration twice a day</description>
        </group>
        <group group_id="P3">
          <title>BIBF 1120 100 mg</title>
          <description>BIBF 1120 100 mg oral administration twice a day</description>
        </group>
        <group group_id="P4">
          <title>BIBF 1120 150 mg</title>
          <description>BIBF 1120 150 mg oral administration twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set: all patients who received study medication and were documented to have taken at least one dose of investigational treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo oral administration twice a day</description>
        </group>
        <group group_id="B2">
          <title>BIBF 1120 50 mg</title>
          <description>BIBF 1120 50 mg oral administration twice a day</description>
        </group>
        <group group_id="B3">
          <title>BIBF 1120 100 mg</title>
          <description>BIBF 1120 100 mg oral administration twice a day</description>
        </group>
        <group group_id="B4">
          <title>BIBF 1120 150 mg</title>
          <description>BIBF 1120 150 mg oral administration twice a day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="10.3"/>
                    <measurement group_id="B2" value="66.7" spread="2.9"/>
                    <measurement group_id="B3" value="67.5" spread="7.4"/>
                    <measurement group_id="B4" value="64.7" spread="8.5"/>
                    <measurement group_id="B5" value="65.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug-related Adverse Events</title>
        <description>The number of patients with drug-related adverse events stratified according to pirfenidone use in each group</description>
        <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Drug-related Adverse Events</title>
          <description>The number of patients with drug-related adverse events stratified according to pirfenidone use in each group</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with Pirfenidone (N = 5, 4, 4, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without Pirfenidone (N = 7, 2, 4, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone</title>
        <description>AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone in the time frame mentioned.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
        <time_frame>pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone</title>
          <description>AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone in the time frame mentioned.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
          <population>Treated set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="165"/>
                    <measurement group_id="O2" value="115" spread="32.4"/>
                    <measurement group_id="O3" value="218" spread="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone</title>
        <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
        <time_frame>pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone</title>
          <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09" spread="173"/>
                    <measurement group_id="O2" value="20.0" spread="64.5"/>
                    <measurement group_id="O3" value="39.7" spread="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone</title>
        <description>AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone in the time frame mentioned.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
        <time_frame>pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone</title>
          <description>AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone in the time frame mentioned.
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="16.7"/>
                    <measurement group_id="O2" value="86.0" spread="62.7"/>
                    <measurement group_id="O3" value="149" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone</title>
        <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
        <time_frame>pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone</title>
          <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone
Detailed outcome measure time frame:
In 50 mg and 100 mg dose group:
BIBF 1120:
days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
In 150 mg dose group:
BIBF 1120:
days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="50.3"/>
                    <measurement group_id="O2" value="13.8" spread="113"/>
                    <measurement group_id="O3" value="23.5" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)</title>
        <description>AUC0-4,ss was calculated as the area under the curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) in the time frame mentioned.</description>
        <time_frame>Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)</title>
          <description>AUC0-4,ss was calculated as the area under the curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) in the time frame mentioned.</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28900" spread="30.7"/>
                    <measurement group_id="O2" value="34400" spread="36.3"/>
                    <measurement group_id="O3" value="45800" spread="26.6"/>
                    <measurement group_id="O4" value="32500" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)</title>
        <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast)</description>
        <time_frame>Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose</time_frame>
        <population>Treated set-Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)</title>
          <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast)</description>
          <population>Treated set-Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11300" spread="22.1"/>
                    <measurement group_id="O2" value="11900" spread="28.9"/>
                    <measurement group_id="O3" value="14600" spread="41.5"/>
                    <measurement group_id="O4" value="11200" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)</title>
        <description>AUC0-4,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) in the time frame mentioned.</description>
        <time_frame>Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)</title>
          <description>AUC0-4,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) in the time frame mentioned.</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28800" spread="6.85"/>
                    <measurement group_id="O2" value="34300" spread="39.9"/>
                    <measurement group_id="O3" value="35000" spread="32.2"/>
                    <measurement group_id="O4" value="35900" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)</title>
        <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast)</description>
        <time_frame>Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)</title>
          <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast)</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12000" spread="23.1"/>
                    <measurement group_id="O2" value="12800" spread="44.3"/>
                    <measurement group_id="O3" value="15300" spread="51.1"/>
                    <measurement group_id="O4" value="12600" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)</title>
        <description>AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after lunch) in the time frame mentioned.</description>
        <time_frame>Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)</title>
          <description>AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after lunch) in the time frame mentioned.</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56600" spread="25.8"/>
                    <measurement group_id="O2" value="72800" spread="40.7"/>
                    <measurement group_id="O3" value="84100" spread="11.4"/>
                    <measurement group_id="O4" value="60900" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)</title>
        <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg Without BIBF 1120 (after lunch)</description>
        <time_frame>Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)</title>
          <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg Without BIBF 1120 (after lunch)</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13500" spread="19.9"/>
                    <measurement group_id="O2" value="14600" spread="20.9"/>
                    <measurement group_id="O3" value="15100" spread="19.5"/>
                    <measurement group_id="O4" value="12900" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)</title>
        <description>AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) in the time frame mentioned.</description>
        <time_frame>Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)</title>
          <description>AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) in the time frame mentioned.</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47000" spread="13.6"/>
                    <measurement group_id="O2" value="71000" spread="40.8"/>
                    <measurement group_id="O3" value="71500" spread="19.1"/>
                    <measurement group_id="O4" value="63600" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)</title>
        <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch)</description>
        <time_frame>Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose</time_frame>
        <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)</title>
          <description>Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch)</description>
          <population>Treated set- Only patients with valid final pharmacokinetic values were analysed</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10700" spread="18.8"/>
                    <measurement group_id="O2" value="12000" spread="37.3"/>
                    <measurement group_id="O3" value="12100" spread="10.7"/>
                    <measurement group_id="O4" value="12500" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal Due to Adverse Event</title>
        <description>Number of patients prematurely discontinued from trial medication due to adverse event.</description>
        <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 1, 2, 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day for cohort 1</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day for cohort 2</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Withdrawal Due to Adverse Event</title>
          <description>Number of patients prematurely discontinued from trial medication due to adverse event.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Pirfenidone (N= 5, 4, 4, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Pirfenidone (N = 7, 2, 4, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background</title>
        <description>Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - No pirfenidone background</description>
        <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 1, 2, 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day for cohort 1</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day for cohort 2</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background</title>
          <description>Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - No pirfenidone background</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma−glutamyltransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background</title>
        <description>Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - With pirfenidone background</description>
        <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 1, 2, 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 50 mg</title>
            <description>BIBF 1120 50 mg oral administration twice a day for cohort 1</description>
          </group>
          <group group_id="O3">
            <title>BIBF 1120 100 mg</title>
            <description>BIBF 1120 100 mg oral administration twice a day for cohort 2</description>
          </group>
          <group group_id="O4">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background</title>
          <description>Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - With pirfenidone background</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypothyroidism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transaminases increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
        <time_frame>baseline and day 35</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
          <population>Treated set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="13.3"/>
                    <measurement group_id="O2" value="-0.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="19.2"/>
                    <measurement group_id="O2" value="2.5" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <description>Change from baseline in pulse rate at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
        <time_frame>baseline and day 35</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <description>Change from baseline in pulse rate at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
          <population>Treated set</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="15.4"/>
                    <measurement group_id="O2" value="1.9" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)</title>
        <description>Change in diffusing capacity for carbon monoxide (DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
        <time_frame>baseline and day 35</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)</title>
          <description>Change in diffusing capacity for carbon monoxide (DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
          <population>Treated set</population>
          <units>mL/min/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.131" spread="1.397"/>
                    <measurement group_id="O2" value="-0.707" spread="2.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)</title>
        <description>Change in Diffusing Capacity for Carbon Monoxide percent of predicted (%DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
        <time_frame>baseline and day 35</time_frame>
        <population>Treated set- Only patients with valid measurements were analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)</title>
          <description>Change in Diffusing Capacity for Carbon Monoxide percent of predicted (%DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
          <population>Treated set- Only patients with valid measurements were analysed.</population>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.660" spread="8.020"/>
                    <measurement group_id="O2" value="-1.193" spread="5.948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Change in forced expiratory volume in 1 second (FEV1) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
        <time_frame>baseline and day 35</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Change in forced expiratory volume in 1 second (FEV1) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
          <population>Treated set</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" spread="0.107"/>
                    <measurement group_id="O2" value="0.036" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function Measurement: Forced Vital Capacity (FVC)</title>
        <description>Change in forced vital capacity (FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
        <time_frame>baseline and day 35</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function Measurement: Forced Vital Capacity (FVC)</title>
          <description>Change in forced vital capacity (FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
          <population>Treated set</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.081" spread="0.175"/>
                    <measurement group_id="O2" value="0.050" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)</title>
        <description>Change in Forced Vital Capacity percent of predicted (%FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
        <time_frame>baseline and day 35</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo oral administration twice a day for cohort 3</description>
          </group>
          <group group_id="O2">
            <title>BIBF 1120 150 mg</title>
            <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)</title>
          <description>Change in Forced Vital Capacity percent of predicted (%FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.</description>
          <population>Treated set</population>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.311" spread="5.193"/>
                    <measurement group_id="O2" value="1.432" spread="2.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>after the first drug intake until 28 days from the last treatment administration, up to 60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo oral administration twice a day for cohort 1, 2, 3</description>
        </group>
        <group group_id="E2">
          <title>BIBF 1120 50 mg</title>
          <description>BIBF 1120 50 mg oral administration twice a day for cohort 1</description>
        </group>
        <group group_id="E3">
          <title>BIBF 1120 100 mg</title>
          <description>BIBF 1120 100 mg oral administration twice a day for cohort 2</description>
        </group>
        <group group_id="E4">
          <title>BIBF 1120 150 mg</title>
          <description>BIBF 1120 150 mg oral administration twice a day for cohort 3</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

